Patients with SM have a distinct plasma protein profile
Patients with systemic mastocytosis (SM) have a different plasma protein profile compared to healthy people.
Patients with systemic mastocytosis (SM) have a different plasma protein profile compared to healthy people.
Preliminary results showed that patients receiving bezuclastinib had better results than patients receiving a placebo in a clinical trial.
RNA-based testing significantly enhanced the detection of KIT mutations, which is critical for diagnosing systemic mastocytosis.
A new study will examine a treatment for patients with systemic mastocytosis with an associated hematologic neoplasm.
Imatinib is a treatment for patients with aggressive SM without the KIT D816V mutation or having unknown KIT mutational status.
A 100 mg dose reduced mast cell burden, alleviated debilitating symptoms and improved quality of life compared to placebo.
A new prognostic score confirmed that KIT Inhibitors improve outcomes in patients with advanced systemic mastocytosis (SM).
A new model accurately distinguished between advanced and indolent systemic mastocytosis using blood sample parameters.
Undiagnosed systemic mastocytosis (SM) led to bleeding complications in a patient with a peanut allergy reaction.
The study results challenge recommendations that people with systemic mastocytosis should avoid certain food and drugs entirely.